Outcomes Mixed on Different Stent Types in STEMI
Drug-eluting stents tied to lower adverse events rate, higher cardiac death rate than bare-metal
THURSDAY, June 17 (HealthDay News) -- Patients with ST-segment elevation myocardial infarction (STEMI) who receive drug-eluting stents (DES) may have a lower rate of major adverse cardiac events than those who receive bare-metal stents (BMS), but they are more likely to experience cardiac death, according to research published online June 16 in the Journal of the American College of Cardiology.
Anne Kaltoft, M.D., of the Aarhus University Hospital in Skejby, Denmark, and colleagues randomly assigned 626 patients with STEMI to receive either DES or BMS to compare long-term outcomes among the two groups.
After three years, the researchers found that recipients of DES had a lower rate of major adverse cardiac events than the BMS group (11.5 versus 18.2 percent), along with a lower rate of target lesion revascularization (6.1 versus 16.3 percent). All-cause mortality was similar between the two groups but the DES group had a higher rate of cardiac death (6.1 versus 1.9 percent). In addition, the rate of reinfarction, stent thrombosis, and stroke was similar in the two groups.
"Implantation of DES in patients with STEMI reduces the long-term rate of major adverse cardiac events compared with BMS, but patients with DES had a higher risk of cardiac death not attributed to myocardial infarction or stent thrombosis," the authors write.